Clinical trials: Extensive Stage Small Cell Lung Carcinoma
Extensive-stage Small Cell Lung Cancer
A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Niraparib is a PARP inhibitor. The study is a 2:1 randomized, double-blind, placebo-controlled, multi-center,phase 3 study of ZL-2306 (niraparib) as maintenance therapy following first-line platinum-based chemotherapy in patients…
- Trial name
- NCT03516084
- Testing
- ZL-2306(nirapairb)
- Where
- 33 sites in China
- Volunteers
- 185 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Small Cell Lung Carcinoma
A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
This is a phase IIIB, single-arm, single-country, multicenter study of the safety and efficacy of atezolizumab in combination with carboplatin plus etoposide in patients who have ES-SCLC and are chemotherapy-naive for their…
- Trial name
- MAURIS (NCT04028050)
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- 25 sites in Italy
- Volunteers
- 155 people
- Sponsor
- Hoffmann-La Roche
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and…
- Trial name
- NCT07564401
- Testing
- DJI136
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Small Cell Lung Carcinoma Extensive Disease
Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
This will be an open-label, single-arm, multicenter, Phase IIIb study to determine the safety of durvalumab + etoposide and cisplatin or carboplatin as first-line treatment in patients with extensive stage small-cell lung cancer.
- Trial name
- NCT04449861
- Testing
- Durvalumab plus chemotherapy
- Where
- 30 sites in China
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Extensive Stage Small Cell Lung Cancer
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and paclitaxel combination therapy in patients with relapsed or refractory extensive stage small cell lung cancer.
- Trial name
- NCT06016270
- Testing
- hSTC810 400 mg + Paclitaxel, hSTC810 800 mg + Paclitaxel
- Where
- 8 sites in United States, South Korea
- Volunteers
- 10 people
- Sponsor
- STCube, Inc.
Extensive Stage Small Cell Lung Carcinoma
A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
The purpose of this trial is to compare the progression free survival of LY2510924 + carboplatin + etoposide therapy versus carboplatin + etoposide therapy in participants with extensive-stage disease small cell lung cancer (SCLC)
- Trial name
- NCT01439568
- Testing
- LY2510924, Carboplatin, Etoposide
- Where
- 15 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)
This is a placebo-controlled, double-blind, multicenter, randomized study for preliminary evaluation of the efficacy and safety of combining bevacizumab with cisplatin (or carboplatin) and etoposide in patients with previously…
- Trial name
- NCT00403403
- Testing
- Bevacizumab, Chemotherapy
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Carcinoma, Small Cell
A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer
The purpose of the study is to determine whether the study drug ZK 219477 (also known as SH Y03757A) combined with cisplatin, is effective in the treatment of small cell lung cancer in patients who did not receive prior treatment…
- Trial name
- NCT00359359
- Testing
- Sagopilone (BAY86-5302, ZK 219477), Cisplatin
- Where
- 10 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Bayer
SCLC, Extensive Stage
A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
Evaluate Clinical Efficacy, Safety and Pharmacokinetics of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Japanese Patients…
- Trial name
- NCT06812260
- Testing
- HLX10+chemo
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Shanghai Henlius Biotech
Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
This study is open to adults with extensive-stage small cell lung cancer. The purpose of this study is to find out how well people with this type of cancer tolerate taking study medicines called obrixtamig and pumitamig.
- Trial name
- NCT07843940
- Testing
- Obrixtamig, Pumitamig, Carboplatin
- Where
- 27 sites in United States, Australia and 8 more
- Volunteers
- 55 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
This study will gather and compare data about the effectiveness and safety of two different treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received previous chemotherapy.
- Trial name
- NCT00043927
- Testing
- topotecan/cisplatin, etoposide/cisplatin
- Where
- 176 sites in United States, Austria and 32 more
- Volunteers
- 760 people
- Sponsor
- GlaxoSmithKline
Small Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory.
- Trial name
- NCT06780137
- Testing
- Gocatamig, Ifinatamab Deruxtecan (I-DXd), Durvalumab
- Where
- 48 sites in United States, Argentina and 10 more
- Volunteers
- 327 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive-stage Small Cell Lung Cancer
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
This randomized, double-blinded, placebo-controlled phase III, multicenter study is designed to evaluate the safety and efficacy of SHR-1316 in combination with carboplatin plus (+) etoposide compared with treatment with placebo…
- Trial name
- NCT03711305
- Testing
- SHR-1316, Carboplatin, Etoposide
- Where
- 2 sites in China
- Volunteers
- 462 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Small Cell Lung Carcinoma
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer
The purpose of this study is to determine whether the study drug is effective and safe in the first line treatment of patients with small cell lung cancer
- Trial name
- NCT00299390
- Testing
- Sagopilone (BAY86-5302, ZK 219477)
- Volunteers
- 10 people
- Sponsor
- Bayer
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
- Trial name
- NCT06726148
- Testing
- ECI830, ribociclib, fulvestrant
- Where
- 33 sites in United States, Australia and 14 more
- Volunteers
- 280 people
- Sponsor
- Novartis Pharmaceuticals
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage…
- Trial name
- NCT07892625
- Testing
- HS-20093 for Injection, ZG006, Adebrelimab Injection
- Volunteers
- 338 people
- Sponsor
- Hansoh BioMedical R&D Company
Solid Tumor, Extensive-stage Small Cell Lung Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
This first-in-human (FIH) trial aimed to establish a safe dose of BNT411 as a monotherapy and in combination with atezolizumab, carboplatin and etoposide.
- Trial name
- NCT04101357
- Testing
- BNT411, Atezolizumab, Carboplatin
- Where
- 12 sites in United States, Germany and 2 more
- Volunteers
- 54 people
- Sponsor
- BioNTech SE
Small Cell Carcinoma of Lung
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer deaths worldwide; in 2022, there were approximately 2.48 million new cases and 1.8 million deaths from lung cancer globally.
- Trial name
- NCT07550842
- Testing
- BL0020, Toripalimab
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Extensive-stage Small Cell Lung Cancer
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared…
- Trial name
- NCT04702880
- Testing
- BMS-986012, Carboplatin, Etoposide
- Where
- 39 sites in United States, Australia and 9 more
- Volunteers
- 135 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing…
- Trial name
- SANTANA-225 (NCT06939036)
- Testing
- 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab
- Where
- 7 sites in United States, Australia
- Volunteers
- 2 people
- Sponsor
- Ariceum Therapeutics GmbH